Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

AbbVie’s model based fair value has been adjusted only slightly, moving from US$248.29 to US$248.86, which keeps the overall price target essentially stable in dollar terms. That small change sits ...

Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 10:00 pm EDT on March 25, 2026 / 10:00 am HKT on March 26, 2026. To access the Chinese language investor event or ...

Jamie Campbell has been announced as guest speaker for 2026 Federation of Northern Ontario Municipalities conference ...